- Precigen Inc PGEN presented data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from the Phase 1 portion of the Phase 1/1b study of PRGN-3005 UltraCAR-T in advanced-stage platinum-resistant ovarian cancer patients.
- The company says that patients in the IV plus lymphodepletion arm showed stable or partial response in 90% of the individual target lesions. The case study demonstrated that repeat dosing further decreased tumor burden.
- Also Read: Precigen Regains Rights To CAR-T Platform For Hematological, Solid Tumor Indications.
- PRGN-3005 was well-tolerated with a low incidence of treatment-related adverse events (TRAEs), no dose-limiting toxicities (DLTs), and no neurotoxicity.
- PRGN-3005, administered intraperitoneally or intravenously at doses as low as 2 million CAR-T cells, showed a dose-dependent expansion and encouraging persistence in peripheral blood.
- Best responder achieved stable disease for more than 18 months after failing nine prior lines of treatment; results were achieved with two doses of UltraCAR-T cells in the low millions.
- Incorporating lymphodepletion before IV infusion led to an efficacy signal as demonstrated by a decrease in tumor burden in 67% (6/9) of patients, with concurrent decreases in CA125 at Day 35 in 89% (8/9) of patients and stable or partial response in 90% of the individual target lesions.
- PRGN-3005 UltraCAR-T cells are currently being evaluated in the Phase 1b dose expansion study at Dose Level 3 via IV infusion with lymphodepletion and incorporating repeat dosing.
- Price Action: PGEN shares closed at $1.34 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
